Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12744530 | 0.84 | DRD2 (0.64) | DRD2DRD4DRD1KCNH2 | |
| SCHEMBL12744529 | 0.83 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CMTNR1B | |
| SCHEMBL16625803 | 0.81 | MTNR1B (0.47) | DRD2DRD4PDE4DDRD1KCNH2 | |
| SCHEMBL12744524 | 0.81 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4CMTNR1B | |
| SCHEMBL16625795 | 0.80 | DRD2 (0.45) | DRD2DRD4DRD1KCNH2MTNR1B | |
| SCHEMBL16625800 | 0.78 | GRIN2C (0.46) | DRD2DRD4MTNR1B | |
| SCHEMBL11936777 | 0.74 | DRD2 (0.57) | DRD2PDE4DDRD1KCNH2MTNR1B | |
| SCHEMBL21328362 | 0.71 | PDE4D (0.53) | DRD2DRD4PDE4DDRD1KCNH2 | |
| SCHEMBL8741257 | 0.71 | PARP1 (0.61) | DRD2DRD4DRD1 | |
| SCHEMBL16625833 | 0.71 | DRD2 (0.61) | DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181237-B2 | Substituted berbines and their synthesis | MALLINCKRODT LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | SUCAMPO PHARMA AMERICAS LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | TYMS, NME2, TYMP | DRD2 2522/4885DRD4 2290/4885PDE4D 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.